{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.92","value":"-17.07"},{"groupId":"OG001","spread":"0.91","value":"-18.16"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"213"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"title":"Loss of Appetite"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.91","value":"-19.35"},{"groupId":"OG001","spread":"0.90","value":"-19.45"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"213"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"title":"Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.58","value":"-21.22"},{"groupId":"OG001","spread":"0.57","value":"-22.09"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"213"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"title":"Cough"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.57","value":"-14.46"},{"groupId":"OG001","spread":"0.57","value":"-15.93"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"213"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"title":"Shortness of Breath"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.25","value":"-1.58"},{"groupId":"OG001","spread":"0.25","value":"-1.94"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"213"},{"groupId":"OG001","value":"216"}],"units":"Participants"}],"title":"Blood in Sputum"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.59","value":"-13.57"},{"groupId":"OG001","spread":"0.59","value":"-14.69"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"213"},{"groupId":"OG001","value":"216"}],"units":"Participants"}],"title":"Pain"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.67","value":"-15.91"},{"groupId":"OG001","spread":"0.67","value":"-16.15"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"213"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"title":"Symptom distress"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.83","value":"-14.43"},{"groupId":"OG001","spread":"0.82","value":"-15.60"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"213"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"title":"Interference with Activity Level"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.95","value":"-16.21"},{"groupId":"OG001","spread":"0.94","value":"-18.12"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"213"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"title":"Global Quality of Life"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.57","value":"-12.17"},{"groupId":"OG001","spread":"0.57","value":"-13.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"213"},{"groupId":"OG001","value":"216"}],"units":"Participants"}],"title":"Average Symptom Burden Index"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.62","value":"-12.00"},{"groupId":"OG001","spread":"0.61","value":"-12.71"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"213"},{"groupId":"OG001","value":"216"}],"units":"Participants"}],"title":"Total LCSS"}],"denoms":[{"counts":[{"groupId":"OG000","value":"224"},{"groupId":"OG001","value":"225"}],"units":"Participants"}],"description":"The LCSS consisted of 9 items: 6 items focused on lung cancer symptoms \\[loss of appetite, fatigue, cough, dyspnea (shortness of breath), hemoptysis (blood in sputum), and pain\\] and 3 global items (symptom distress, interference with activity level, and global quality of life). Participant responses to each item were measured using visual analogue scales (VAS) with 100-millimeter (mm) lines. A higher score for any item represented a higher level of symptoms/problems. The LCSS total score was defined as the mean of all 9 items. Average symptom burden index (ASBI) was calculated as the mean of the six symptom-specific questions from the LCSS. Potential scores range from 0 (for best outcome) to 100 (for worst outcome).","dispersionType":"Standard Error","groups":[{"description":"Part B: 10 mg/kg ramucirumab administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met.","id":"OG000","title":"Part B: Ramucirumab+ Erlotinib"},{"description":"Part B: Placebo administered every 2 weeks IV in combination with 150 mg erlotinib daily orally.\n\nParticipants may continue to receive treatment until discontinuation criteria are met.","id":"OG001","title":"Part B: Placebo+ Erlotinib"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Part B: All randomized participants who completed the LCSS at baseline and at least once post-baseline. Per protocol, Part A did not evaluate efficacy.","reportingStatus":"POSTED","timeFrame":"Baseline, End of Study (Up To 37 Months)","title":"Part B: Best Change From Baseline on the Lung Cancer Symptom Scale (LCSS)","type":"SECONDARY","unitOfMeasure":"millimeter"}